Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...

In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23 ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing.

Zydus Lifesciences share price trading maginally lower in the opening trade on October 3 despite the company received ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...